Jacques Rossouw

Jacques Rossouw

Auto-generated profile, based on publicly available information

Jacques Rossouw

Division of Clinical Pharmacology, Department of Medicine, University of Cape Town

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2019 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
HSHanna Svitina
Hanna Svitina
RSRoan Swanepoel
Roan Swanepoel
JRJacques Rossouw
Jacques Rossouw
MNMmbulaheni Happiness Netshimbupfe
Mmbulaheni Happiness Netshimbupfe
Chrisna GouwsChrisna Gouws
Chrisna Gouws
Josias HammanJosias Hamman
Josias Hamman
The skin is the largest organ and functions as a barrier to protect the underlying tissues against the elements and pathogens, while also fulfilling many physiological roles and biochemical functions such as preventing excessive water loss. Skin disorders vary greatly in terms of origin, severity, symptoms and affect persons of all ages. Many plants have been used for medicinal purposes since ancient times including the treatment of skin disorders and diseases. Aloe represents one of the earliest medicinal plant species mentioned in antique scriptures and even in rock art dating back thousands of years. Different Aloe species and materials have been used in the prevention and treatment of skin related disorders. Aloe vera is the most commonly used Aloe species for medicinal purposes. Some of the most prominent skin related applications and disorders that Aloe materials have been investigated for are discussed in this paper, which include cosmetic, radiation, cancer, wound and antimicrobial applications. Both in vitro and in vivo studies are included in the discussions of this paper and comprehensive summaries of all these studies are given in tables in each section. Although some contradictory results were obtained among studies, certain Aloe materials have shown excellent efficacy and exhibited potential for the treatment of skin related disorders and cosmetic applications.

10 July 2019 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
CWClarissa Willers
Clarissa Willers
HSHanna Svitina
Hanna Svitina
MRMichael J. Rossouw
Michael J. Rossouw
RSRoan A. Swanepoel
Roan A. Swanepoel
Josias HammanJosias Hamman
Josias Hamman
Chrisna GouwsChrisna Gouws
Chrisna Gouws

2 September 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
JRJacques Rossouw
Jacques Rossouw
RWRobert Wallis
Robert Wallis
HKHardy Kornfeld
Hardy Kornfeld
ASAmit Singhal
Amit Singhal
GMGary Maartens
Gary Maartens
RWRoeland E. Wasmann
Roeland E. Wasmann
Metformin is under investigation as adjunctive host-directed therapy for tuberculosis (TB), which might interact with first-line TB treatment. We used population pharmacokinetic modeling to assess whether metformin alters first-line TB-drug pharmacokinetics in HIV/TB-coinfected adults without diabetes. Rifampicin, isoniazid, and pyrazinamide pharmacokinetics were investigated in participants from a randomized clinical trial of adjunctive metformin (500 mg twice daily to week 12) in adults starting HIV-associated TB treatment. Antiretroviral therapy (ART)-naïve participants initiated dolutegravir-based ART within 8 weeks. Intensive and semi-intensive sampling was conducted at week 5; concentration–time data were analyzed using non-linear mixed-effects modeling. Data from 78 individuals (43 receiving metformin, median weight 60.8 kg, 62.8% male, 79.5% on ART) were analyzed. Rifampicin and pyrazinamide were described by one-compartment models with linear elimination; typical clearances were 15.8 L/h (95% CI: 13.5–18.7) and 3.88 L/h (95% CI: 3.54–4.08), respectively. Isoniazid followed a two-compartment model with a mixture model for acetylator status; clearance was 10.5 L/h (95% CI: 9.44–11.9) in slow acetylators and 28.8 L/h (95% CI: 25.6–31.0) in fast/intermediate acetylators. Metformin reduced isoniazid bioavailability by 15.6% (95% CI: 4.45–26.4%, P < 0.009) and rifampicin bioavailability by 24.0% (95% CI: 7.83–36.3%, P < 0.007), decreasing the area under the curve from 0 to 24 h from 18.2 to 15.6 mg·h/L and from 35.9 to 27.1 mg·h/L, respectively. No significant effect on pyrazinamide was detected. We found that non-diabetic patients on metformin had lower isoniazid and rifampicin bioavailability. Lowered rifampicin exposure might be clinically relevant; simulations suggest that this could be offset by a single 150 mg rifampicin dose. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT04930744 .